Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States

Abstract

The economic burden of AESIs is substantial, with infections the most expensive, followed by cytopenia and GI toxicity. New therapies that can improve outcomes in relapsed Ph- B-cell ALL while offering a favorable safety profile are needed.

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

“…The model assumed that in lieu of subsequent treatments, some patients may receive an allo-SCT. Allo-SCT costs were determined by multiplying the cost of an allo-SCT including 24 months of follow-up ($416,823[ 10 , 23 ]) by the proportion of patients receiving an allo-SCT by treatment arm (Table 1 ).…”

“…This may be due to advanced age, multiple comorbidities, higher-risk disease features, and heavy pre-treatment [7,8]. In addition to poor clinical outcomes, R/R ALL is also associated with a substantial economic burden [9][10][11], attributed to disease progression and management of adverse events from available treatments [10,12]. Multiple treatment options are currently available for adults with R/R-ALL in the US including those used as a bridge to allo-SCT (blinatumomab [BLIN], inotuzumab ozogamicin [INO]), other CAR-Ts (tisagenlecleucel for patients \ 26 years of age and with R/R B-cell ALL disease in second or later relapse), and CHEMO.…”

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

“…Some clinical characteristics of patients have been associated with the presence of AEs such as sex, risk standard or high (ALL risk category) of neoplastic relapse (more than 5% of blasts) [16] and early response to RICP treatment [17,18]. Studies on the cost of AE in pediatric patients with ALL are scarce; for the adult population, the cost of USD 33,189 was determined for inpatient treatment of febrile neutropenia [19][20][21], the most frequent AE reported in patients with ALL of HIMFG [11]. A systematic review found that hospitalacquired adverse drug reactions (adverse events) translate into £380 million per year in UK while in Canada the overall cost of AE related admission to the emergency department and succeeding hospitalizations was quantified as approximately $13.6 million USD [22].…”

Impacto do perfil sistêmico de pacientes com câncer de boca e orofaringe sobre as toxicidades bucais induzidas pelo tratamento oncológico

“…In a particular study that evaluated costs associated with adverse events, the driver of total costs was hospitalizations, accounting for 94.3% of all costs [44]. Similar findings were also valid for mucositis, and hospitalization often to manage mucositis accounts for the majority of treatment costs [9,5,24,26,36,53].…”

“…We have also included three studies that evaluated costs associated with mucositis in cancer patients but did not specify the cancer treatment [52][53][54]. Bermejo de Las Heras et al [54] evaluated the cost of adverse events in metastatic breast cancer patients and estimated an additional 1620,47 USD associated with mucositis.…”